Skip to content
Study details
Enrolling now

Sildenafil for Microvasculopathy in Chronic TBI

University of Pennsylvania
NCT IDNCT05782244ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

160

Study length

about 3.5 years

Ages

18–70

Locations

1 site in PA

What this study is about

Researchers are testing different doses of sildenafil to see if it can improve blood flow in the brain after a traumatic brain injury. The trial will also look at whether sildenafil improves symptoms and outcomes related to chronic TBI.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Sildenafil Citrate low dose
  • 3.Take Sildenafil high dose
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Cardiovascular Agent [TC] (Phosphodiesterase 5 Inhibitors), GENITO URINARY SYSTEM AND SEX HORMONES

Drug routes

oral (Oral Suspension), oral (Oral Tablet)

Endpoints

Secondary: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0